Repligen Corp (RGEN): Thomas F Jr Ryan , director of Repligen Corp sold 5,000 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were sold at $26.60 per share for a total value of $133,010.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 29, 2016, Thomas F Jr Ryan (director) sold 10,000 shares at $24.59 per share price.On May 13, 2016, Howard Benjamin (other) sold 2,889 shares at $26.72 per share price.Also, On May 19, 2015, James R Rusche (Senior Vice President) sold 15,000 shares at $41.32 per share price.On May 14, 2015, Walter C Herlihy (PRESIDENT, CEO) sold 45,431 shares at $38.97 per share price.
Repligen Corporation: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in Repligen Corporation which led to swings in the share price. The shares opened for trading at $25.12 and hit $27.1299 on the upside , eventually ending the session at $26.63, with a gain of 6.86% or 1.71 points. The heightened volatility saw the trading volume jump to 6,72,262 shares. The 52-week high of the share price is $42.48 and the company has a market cap of $896 M . The 52-week low of the share price is at $20.07.
Repligen Corporation (Repligen) is a life sciences company. The Company develops manufactures and markets bioprocessing products for life sciences and biopharmaceutical companies across the world. The Company is a manufacturer of both native and recombinant forms of Protein A critical reagents used in biomanufacturing to purify monoclonal antibodies which is a type of biologic drug. It also supplies several growth factor products and cell filtration products used to increase cell culture productivity during the bioproduction process. It has developed a series of OPUS chromatography columns for use in clinical-scale manufacturing. It manufactures and sells Protein A and growth factors to life sciences companies under supply agreements and sells chromatography columns as well as media and quality test kits and the Company’s Alternating Tangential Flow (ATF) products directly to biopharmaceutical companies or contract manufacturing organizations or through distributors.